Stralem & Co. Inc. continued to hold its position in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 740,524 shares of the biopharmaceutical company’s stock at the end of the first quarter. Pfizer makes up approximately 2.9% of Stralem & Co. Inc.’s holdings, making the stock its 21st largest position. Stralem & Co. Inc.’s holdings in Pfizer were worth $24,052,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the period. Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Fusion Family Wealth LLC acquired a new position in Pfizer during the fourth quarter worth approximately $109,000. Stanford Investment Group Inc. boosted its position in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 456 shares in the last quarter. Finally, Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares in the last quarter. Institutional investors own 70.80% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) opened at 33.88 on Thursday. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $37.39. The stock has a market cap of $202.19 billion, a price-to-earnings ratio of 28.52 and a beta of 1.02. The company’s 50-day moving average price is $32.70 and its 200 day moving average price is $33.07. Pfizer also was the recipient of unusually large options trading on Tuesday. Stock investors purchased 1,389 call options on the company. This is an increase of 135% compared to the average volume of 590 call options.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The business’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. On average, equities analysts predict that Pfizer, Inc. will post $2.55 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 1st. Investors of record on Friday, May 12th were given a dividend of $0.32 per share. The ex-dividend date was Wednesday, May 10th. This represents a $1.28 dividend on an annualized basis and a yield of 3.78%. Pfizer’s payout ratio is 108.48%.
A number of research firms recently commented on PFE. Barclays PLC set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Thursday, March 16th. Vetr cut Pfizer from a “hold” rating to a “sell” rating and set a $33.45 price target on the stock. in a report on Thursday, March 2nd. Societe Generale reissued a “neutral” rating and issued a $36.00 price target on shares of Pfizer in a report on Thursday, March 23rd. BMO Capital Markets reissued a “hold” rating and issued a $33.00 price target on shares of Pfizer in a report on Tuesday, March 21st. Finally, Sanford C. Bernstein reissued a “buy” rating and issued a $35.00 price target on shares of Pfizer in a report on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus price target of $37.32.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/stralem-co-inc-has-24052000-position-in-pfizer-inc-pfe/1930123.html
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.